Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 21, 2014; 20(11): 2771-2776
Published online Mar 21, 2014. doi: 10.3748/wjg.v20.i11.2771
Published online Mar 21, 2014. doi: 10.3748/wjg.v20.i11.2771
Figure 1 Algorithm for managing chronic hepatitis C virus infection in cancer patients.
1At least 6 mo after cancer remission before initiating myelosuppressive hepatitis C virus (HCV) treatment with interferon-based therapy. Wait 2 years after hematopoietic stem cell transplant before initiation of interferon-based HCV therapy for patients with normal serum creatinine, normal blood counts, off immunosuppressive therapy > 6 mo, and without evidence of original disease recurrence or graft versus host disease[10]. PegIFN: Pegylated interferon.
- Citation: Borchardt RA, Torres HA. Challenges in managing hepatitis C virus infection in cancer patients. World J Gastroenterol 2014; 20(11): 2771-2776
- URL: https://www.wjgnet.com/1007-9327/full/v20/i11/2771.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i11.2771